,000 deaths and 33.4 million cases globally ( 1 ). The majority of these cases occur in the poorest regions of the world. RHD commonly affects the mitral, aortic and occasionally tricuspid valves. Rheumatic pulmonary valve disease is very rare. During heart
Search Results
Isaac Adembesa, Adriaan Myburgh, and Justiaan Swanevelder
Erwan Donal, Elena Galli, Amedeo Anselmi, Auriane Bidaut, and Guillaume Leurent
increase in surgical risk, and may contraindicate open-heart surgery ( 4 ). Therefore, it is now possible to treat aortic, pulmonary, tricuspid valve disease and peri-prosthetic leaks by percutaneous approaches. These approaches are based on the
David Messika-Zeitoun, Ian G Burwash, and Thierry Mesana
is on the horizon. In contrast to many other cardiac conditions, there is no treatment to prevent or slow the progression of valve disease and the only curative treatment is the performance of a valve intervention, surgically or through a
Shaun Robinson, Liam Ring, Daniel X Augustine, Sushma Rekhraj, David Oxborough, Allan Harkness, Patrizio Lancellotti, and Bushra Rana
intervention ( 18 ). The commonest causes of moderate or severe MR include degenerative disease (also referred to as mitral valve prolapse (MVP)) accounting for around 60%, rheumatic valve disease seen in 15% and secondary MR responsible for approximately 20
Catrin Williams, Anca Mateescu, Emma Rees, Kirstie Truman, Claire Elliott, Bohdana Bahlay, Ailsa Wallis, and Adrian Ionescu
Introduction Heart valve disease is ‘the next cardiac epidemic’ ( 1 ) and imposes an increasing drain on health care resources ( 2 ). There are little data about the prevalence of heart valve disease in the old; in major published surveys ( 3
L D Hunter, M Monaghan, G Lloyd, A J K Pecoraro, A F Doubell, and P G Herbst
disease in New Zealand: not all valve disease is rheumatic . Cardiology in the Young 2011 21 436 – 443 . ( https://doi.org/10.1017/S1047951111000266 ) 8 Ranganathan N Lam JH Wigle ED Silver MD. Morphology of the human mitral valve. II. The value
John B Chambers and Richard P Steeds
Valve disease is increasing in prevalence as our population ages ( 1 ) and is commonly regarded as the next cardiac epidemic ( 2 ). Patients are increasingly hard to assess as a result of comorbidities, while more is feasible in terms of
Annari van Rensburg, Philip Herbst, and Anton Doubell
rare disease involving obstruction of the left ventricular outflow (valvular/subvalvular stenosis or coarctation) and inflow (parachute mitral valve or supravalvular mitral membrane) ( 5 ), is an uncommon yet interesting one as it serves to illustrate
Madalina Garbi and Mark J Monaghan
valve disease, being essential for management planning ( 1 , 2 , 3 , 4 ). Quantitative analysis is an integral part of morphology assessment and provides objective evidence for the classification of findings within the normal or abnormal range and
Patrick Savage and Michael Connolly
Background Mitral valve repair is the gold standard treatment for degenerative mitral valve disease with superior perioperative and long-term morbidity and mortality outcomes vs mitral valve replacement. The 10 year survival freedom from redo
